News & Media

Access press releases, presentations, and corporate information.

Press Room

News Releases

05/06/25

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

05/06/25

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

05/05/25

Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

05/05/25

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

04/30/25

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

04/24/25

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

04/14/25

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

Resources

About Neurocrine Biosciences

Learn About Us and Our Work

Clinical Studies

Check Out What We’re Studying

Pipeline

Check Out What We’re Working On